Kidney disease guideline profusion and confusion: Unintended consequences of different perspectives and definitions

American Journal of Kidney Diseases

Volumn 63, Issue 5, 2014, Pages 749-752

  Levin, Adeera ^a   Stevens, Paul E ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Kent Kidney Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ALBUMINURIA; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; DISEASE CLASSIFICATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MEDICAL SOCIETY; NOTE; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; PROTEINURIA; PUBLICATION; SCIENTIST; SCREENING;

HUMANS; MASS SCREENING; RENAL INSUFFICIENCY, CHRONIC;

EID: 84898897513     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.02.004     Document Type: Editorial

References (11)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 suppl 1 2002 S1 S266
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int Suppl 3 2013 1 150
3. A. Qaseem, R. Hopkins, D. Sweet, M. Starkey, and P. Shekelle Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the Clinical Guidelines Committee of the American College of Physicians Ann Intern Med 159 12 2013 835 847
4. P.E. Stevens, and A. Levin Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline Ann Intern Med 158 11 2013 825 830
5. G.H. Guyatt, A.D. Oxman, and R. Kunz et al. Going from evidence to recommendations BMJ 336 2008 1049 1051
6. V.A. Moyer on behalf of the U.S Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 8 2012 567 570
7. KDIGO BP Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 2012 337 414
8. P.A. James, S. Oparil, and B.L. Carter et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 5 2014 507 520
9. L.A. Tomlinson, G.A. Abel, and A.N. Chaudhry et al. ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study PLoS One 8 11 2013 e78465
10. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Kidney Int Suppl 3 2013 259 305
11. C. Baigent, M.J. Landray, C. Reith SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 2011 2181 2192